Member Info for dallo

BMS's Cobenfy Adept 1 Phase 3 trial on Alzheimers is due to report within the next month or so

This is the first of 3 Cobenfy Adept trials , the remaining 2 to report next year.

BMS say its needs 2 out the 3 trials to be positive before it is satisfied that material change in Alzheimers psychology is achievable.

The market potential to alleviate Alzheimers patients' distress and hallucinations is enormous and would lead to a major breakthrough in patient well-being and care.

A cure for dementia and Alzheimers is still the holy grail but a quality of life enhancing drug would be a major advance and a blockbuster imho.

Golfnut

I think it was a chat room on Telegram who picked up the press speculation in Norway or somewhere close to Nordic Capital HQ and discussed the £2 possible offer.

Puretech in its RNS announcement said it had to act due to "Press speculation " and Nordic Capital walked maybe as a result of the press leak and insider trading insinuations.

Anyway it is water under the bridge now and Nordic Capital can come back again in 2 weeks if they so wish.

Unlikely but possible.

The Puretech share price is thoroughly smashed now and still no buyers around.

I have exhausted my ammo now after buying a few more yesterday.

A tough gig at the moment for us all here as every shareholder is losing money.

The Nordic Capital tentative offer discussions with Puretech were scuppered by social media postings before these discussions could get serious.

A potential offer price of , allegedly, £2 a share was mentioned by a poster(s) on one of the sites.

Nordic Capital 6 months prohibition from making a further approach/offer expires in 2 weeks.

With no permanent Chairman or CEO and disgruntled shareholders allied to a near cash market cap, Puretech's Board need to mount its defences quickly to avoid a low ball offer being made and accepted.

Finally LYT-100 at Phase 3 stage development in a poorly served IPF drug market had significant value right now.

Doff

Firstly Interim Chair Barber -Lui and Interim CEO Lyne are not new management as such and have been part of the Board and management for years .

Also we are no longer in a closed period after the Interims but there may be other factors at play preventing any insider from buying shares such as takeover talks or impending news on Celea FDA discussions and Celea financing or Cobenfy revenues update from BMS et al.

Lyne has been appointed to do a job as Interim CEO and the Institutional investors are calling the shots .

Something has to give soon imho.

Topped up again with another 6,000 shares

This is getting ridiculous now

Down 20% in 1 month

JSB

When it reached its low in April and cash and market cap were almost the same it inspired a bid from Nordic Capital.

It looks likely this could happen again imho

JSB

And the SP is nearly back to the all-time lows of April.

Bizarre

And now down another 2%

Wow

Hard to believe

Oldernowiser

Frustrating indeed particularly as the Nasdaq Biotechnology Index is up nearly 30% since its low in May 2025.

Tuscany

The cost of a Phase 3 clinical trial for IPf lung disease with a thousand patients in the study would cost around $60 million .

This not a huge amount of funding even if you add other costs to run Celea Therapeutics during the next 2 years.

Which begs the question as to why Puretech doesn't conduct the trial itself and keep 100% of Celea for a while longer

Lesley

Don't despair

Market Cap £275m

Cash £230m

So £45m for Celea, Gallop, Seaport and minimum £250m in Cobenfy royalties.

Keep the faith

ATB

Another good news RNS on Seaport commencing Phase 1 trial on its Glyph General Anxiety drug met with utter disdain by the market .

Sadly Puretech is totally unloved by investors apart from the small band of diehards on this board.

Even the posters on ADVFN have given up.

Still nothing from UBS .

Hopefully something stirring in the background.

The wait goes on.

ATB

803

I did say OVER $1B if trial is successful.

However given the market is currently only valuing Puretech on its cash balance and part of its Cobenfy royalties and ascribing zero value to Celea , Seaport or Gallop we seem to be the lone voices crying in the wilderness.

Hopefully we will be vindicated soon as I am not getting any younger !

Incredible indeed.

Also Seaport Therapeutics will have a valuation of over $1billion if its Phase 2B trials for GlyphAllo , its major Antidepressant drug , are successful.

On a more optimistic note, we could be faced with a bizarre anomaly of Celea Therapeutics being valued at over $1 billion while Puretech is valued at c$350m.

Sale of late stage potential blockbuster drugs are exceeding $1billion in recent deals so it will be interesting to see how Celea is structured financially.

ATB

JSB

I honestly don't think the Directors and management will have the luxury of kicking the can down the road for another 6/8 months .

Nordic Capital allegedly made a bid of c£2 so with the SP now nearing £1 , a 100% premium would seal the deal imho.

Any views of the appointment of an Interim Chairman and CEO....doesn't inspire confidence in the Board imho.

Large institutions control c65% of the shares and I feel they all want out .

Lyne appears a stop gap so hopefully a bid is imminent.

SP now 114p

Must be tempting a few potential bidders to make a move .

Hence the need for some positive action by management in the very near term imho

Snowking

If ever Puretech needed a positive catalyst(s) it is now as the SP crawls along the all time low bottom down 26% year to date and 60% over past 5 years.

I am looking at some Pharma shares rocketing on minor developments while Puretech stagnates for months / years.

Hopefully Robert Lyne has something up his sleeve over the coming months .

It is the opportunity costs of holding Puretech that is frustrating as well.

Cobenfy 2nd Quarter revenues should be out soon and hopefully up on the $27m 1st Quarter.

Celea Therapeutics is obviously going to be key to ascertain what valuation the market will assign it once financial structure is agreed.

Some news from Seaport on its Phase 2B drug trial would also be welcomed.

ATB

Rock

Yes things can turn around very quickly in Pharma stocks.

I just sold my large position in another Pharma share after 8 years holding it and was down over 80% at one stage but has moved 500% in past 8 months so finally out at a profit...patience / stupidity rewarded.

I have used some of the proceeds to buy more Puretech in past 3 days so fingers crossed.

Incidentally the Pharma stock has nothing but hype and hope and no funds.

Puretech is in a totally different situation and hopefully the TikTok brigade will pile in like they did with the other Pharma in question.

ATB

Rock

Why a UK focus for a 100% US centric business with zero connection to the UK?

Headquarters in Boston, Board meetings in Boston, all R&D and staff in Boston and all activities denominated in US $ with an existing Nasdaq listing.

The appointment of two UK Non Executive Directors is really stupid in this context .

What will their roles be other than a few trips to the US for Board meetings.

A UK listed company with no Board meeting in the UK is not unusual but you must ask what is the point unless you are another nationality AIM company who was desperate for UK funding not a US Pharma with access to huge Wall Street funding and Wall Street Investment analysts coverage.

Change of strategy now in play imho